Jasper Therapeutics, Inc. JSPR 深 滬
等待開盤 05-19 09:30:00 美东时间
0.8065
-0.044
-5.13%
華盛通- 最 高0.865
- 今 開0.865
- 成交量 21.31万股
- 最 低 0.78
- 昨 收 0.8501
- 總市值 2257.94万
- 52周最高 7.19
- 市盈率 靜 --
- 換手率 0.76%
- 52周最低 0.623
- 委 比 83.87%
- 總股本 2799.68万
- 歷史最高 188.80
- 量 比 0.70
- 振 幅 10.00%
- 歷史最低 0.623
- 每 手 1
- 風險率 1.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
TD Cowen Downgrades Jasper Therapeutics to Hold
TD Cowen analyst Yaron Werber downgrades Jasper Therapeutics (NASDAQ:JSPR) from Buy to Hold.
05-16 00:45
RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3
RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Perform and lowers the price target from $4 to $3.
05-15 22:05
美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $7
Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the price target from $12 to $7.
04-02 01:06
Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.64) by 50.31 percent. This is a 80.25 percent increase over losses of $(1.62) per share
03-31 04:53
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock rose 19.6% to $1.4 during Frid...
02-13 20:05
Jasper Therapeutics Reports Updated Clinical Data From BEACON Phase 1b/2a Study Of Subcutaneous Briquilimab In Adult Participants With CSU, As Well As From Open Label Extension Study In CSU And CIndU
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension
01-08 20:09
Jasper Stock Jumps After Promising New Asthma Study Results
Jasper Therapeutics released positive data from a study of subcutaneous briquilimab for allergic asthma treatment.
2025-12-03 00:14
Market-Moving News for December 2nd
MDB: 24% | MongoDB shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY26 guidance above estimates. Also, the company issued Q4 guidance above
2025-12-02 20:12
